Praxis Precision Medicines (PRAX) Revenue (2023 - 2024)
Praxis Precision Medicines' (PRAX) quarterly Revenue came in at $7.5 million in Q4 2024, up 1349.13% year-on-year from $515000.0 in Q1 2024, and up 2371.19% quarter-over-quarter from $302000.0 in Q3 2024.
Praxis Precision Medicines (PRAX) Revenue (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' Revenue history runs 2 years deep, the most recent figure standing at $7.5 million for Q4 2024.
- On a quarterly basis, Revenue rose 1349.13% year-over-year to $7.5 million in Q4 2024; TTM through Sep 2025 was $7.5 million, a 364.98% increase from a year earlier, with the FY2024 full-year figure at $8.6 million, up 249.53% from the prior year.
- Revenue grew to $7.5 million in Q4 2024 per PRAX's latest filing, from $302000.0 in the prior quarter.
- Across five years, Revenue topped out at $7.5 million in Q4 2024 and bottomed at $302000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Praxis Precision Medicines | 9.37 Bn | 8.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 302,000.00 |
| Jun 30, 2024 | 357,000.00 |
| Mar 31, 2024 | 431,000.00 |
| Dec 31, 2023 | 515,000.00 |
| Sep 30, 2023 | 468,000.00 |
| Jun 30, 2023 | 781,000.00 |
| Mar 31, 2023 | 683,000.00 |